Objective: Aortic valve replacement (AVR) is the standard treatment for severe, symptomatic aortic stenosis (AS). However, many patients are not referred for surgery and fewer undergo AVR. Transcatheter aortic valve implantation (TAVI) has emerged as a solution for high-risk AS patients. We sought to measure the impact of TAVI on the undertreatment of AS. Methods: Patients with AS were identified by retrospective medical record review and evaluation of echocardiograms were performed in a single-center tertiary-care institution. A total of 179, 183, 214, and 265 patients had AS in 2006, 2007, 2008, and 2009, respectively, with the introduction of TAVI occurring in 2008 and continuing through 2009. The primary endpoints were the rates of unoperated AS and surgical referral. Results: The rates of unoperated AS were 50.6% before TAVI and 40.7% after TAVI ( p = 0.002). Referral rates to surgery were 63.6% before TAVI and 74.1% after TAVI ( p = 0.003). Reasons for nonreferral were patient-family decision, perceived high operative risk, and the presence of comorbidities. Operative mortality was 3.7% and not statistically significant different between years. Three-year patient survival was 82.5% in the AVS group and 43.9% in the UNOP group ( p < 0.001). Conclusions: The introduction of TAVI was associated with an increase in surgical referrals and a decrease in the rate of unoperated AS. This positive impact was due to increases in both TAVI and AVR volume. Increased volume was not associated with worse patient survival. A significant population of patients with AS are still treated medically. #
Introduction
The natural history of aortic stenosis (AS) after the onset of symptoms is poor. The average life expectancy of patients with severe, symptomatic AS is 2-3 years with a significant risk of sudden death [1] . Open heart surgery with aortic valve replacement (AVR) remains the standard treatment for patients with severe, symptomatic AS [1] . Current operative outcomes after isolated AVR continue to improve with an in-hospital mortality of 2.6% nationally [2] and below 1% in high-volume centers in the United States [3] .
The undertreatment of AS remains a significant clinical problem. A comprehensive study of valvular heart disease in Europe showed that 33% of patients with severe, symptomatic AS were treated nonoperatively [4] . The commonly cited reasons for not offering AVR have included advanced age and significant comorbidities [5] . However, the improper overestimation of operative risk may be a significant deterrent to surgical referral, therefore denying a potentially life-saving procedure [6] [7] [8] .
Transcatheter aortic valve implantation (TAVI) has been introduced as an alternative treatment for high-risk patients with AS. Current investigational devices can be deployed without the need for a sternotomy or cardiopulmonary bypass. This less-invasive approach is an attractive feature to both patients and physicians. The goal of this study was to determine the impact of the introduction of a TAVI program on the rate of unoperated AS at a single-center tertiary-care institution.
Materials and methods

Study design
This study was approved by the Institutional Review Board (IRB) at Northwestern University (IRB project # STU00012288). The IRB waived the requirement of individual patient consent, as the analysis was retrospective in nature. Patients with AS were identified by retrospective evaluation of echocardiograms. From 2006 through 2009, an electronic term search of 120 327 echocardiographic reports at our institution was performed for documented severe AS (Fig. 1 
Patient cohorts
The characteristics of all patients with AS are shown in Table 1 , grouped by the 2 years pre-TAVI and the 2 years post-TAVI. A total of 362 patients were in the pre-TAVI years and 479 in the post-TAVI years. Gender, age, body mass index (BMI), diabetes, hypertension, renal failure, congestive heart failure, coronary artery disease (CAD), ejection fraction, and previous sternotomies did not differ between the groups. An increase in chronic lung disease from 15.8% to 24.5% was observed ( p = 0.002).
Study endpoints
The primary endpoints were whether the patient received aortic valve surgery (AVS) and if the patient was referred to cardiac surgery. Secondary endpoints were primary reason for not undergoing AVS, operative outcomes, and patient survival. Reasons for patients not undergoing treatment were directly determined by documented statements from the primary care physicians, cardiologists, and/or cardiac surgeons involved 
Statistical analysis
Patient characteristics were compared in pre-TAVI versus post-TAVI years, as well as by UNOP or AVS status. Chi-square test and exact Fisher's tests were used for categorical variables and t-tests were used for continuous variables. Variables with distributions that deviated from normality were reported by median and interquartile range (IQR) rather than by conventional mean AE standard deviation (SD). Differences in long-term all-cause mortality between the UNOP and AVS groups were tested using the Kaplan-Meier survival curve method with log-rank test. Cox proportional hazards regression was used to find independent predictors of mortality. SAS software (Statistical Analysis Software (SAS) version 9.2, www.sas.com, Cary, NC, USA) was used to perform statistical analysis. p-values less than 0.05 were considered significant.
Results
Treatment and referral rates
In the pre-TAVI years, 93 and 86 patients received an AVR in 2006 and 2007, respectively. In the post-TAVI years, 122 and 162 patients received either an AVR or a TAVI in 2008 and 2009, respectively. Twenty-seven TAVI procedures were performed in the post-TAVI years. AVR volume increased by 78 cases from the pre-TAVI to post-TAVI years. Fig. 2 demonstrates the significant decrease in the rate of UNOP AS patients from 50.6% (183/362) in the pre-TAVI years to 40.7% (195/479) in the post-TAVI years ( p = 0.002). In addition, referral rates of patients with severe, symptomatic AS for cardiac surgery evaluation increased from 63.8% (231/362) in the pre-TAVI years to 74.1% (355/479) in the post-TAVI years ( p = 0.003).
Patient survival
Patient characteristics of patients that were treated medically (UNOP) compared to those that were treated with an AVS are shown in Table 2 . The AVS group had a younger mean age, higher BMI, less renal failure, dialysis, and less congestive heart failure. The UNOP group, however, had less CAD. Average length of follow-up was 23.5 AE 15.0 months in the AVS group and 17.8 AE 15.4 months in the UNOP group. Allcause long-term survival in the entire group was 70.3% at 4 years. The AVS group had significantly higher survival rates compared with the UNOP group (Fig. 3) . Overall, 1-and 3-year patient survivals were 89.4% and 82.5%, respectively, in the AVS group compared with 63.9% and 43.9% in the UNOP group.
Multivariable analysis
Independent predictors of mortality (Table 3) disease (HR = 2.125, p < 0.001), renal failure (HR = 1.618, p = 0.0.24), congestive heart failure (HR = 1.755, p < 0.001), and ejection fraction (HR = 0.848 for 10-unit increase, p < 0.001). Therefore, AVS had a strong protective effect with an adjusted risk reduction of 62.0%.
Short-term complications following AVS operation
Patients that underwent AVS in 2008-2009, after the introduction of TAVI, had more comorbidities when compared with patients who had AVS in 2006-2007 (not shown). In particular, the patients in the later years had a higher prevalence of hypertension ( p = 0.002) and chronic lung disease ( p < 0.001). The Ambler Score [9] of predicted inhospital mortality gave an overall median of 5.5% in the pre-TAVI years and 7.3% in the post-TAVI years, but this difference was not statistically significant ( p = 0.472). Concomitant procedures were performed in 245 (52.9%) patients (Table 4 ). In the pre-TAVI years compared with the post-TAVI years, the number of concurrent coronary artery bypass grafting (CABG) procedures decreased, whereas the number of concurrent aortic root reconstructions and ascending aorta replacements increased. There were no significant differences in short-term complications or operative mortality (3.7%).
Reasons for non-treatment
Patient-family decision, high operative risk (perceived and/or calculated), and the presence of comorbidities are the top three documented reasons for patients not undergoing AVR (Table 5 ). Advanced patient age as well as the AS not being perceived as severe were also commonly noted. Other reasons include waiting for enrollment in the TAVI program, seeking a second opinion, insurance problems, and not being referred. There are no significant differences in the distribution of these reasons in the pre-TAVI and post-TAVI years. [ ( ) T D $ F I G ] Fig. 3 . Patient survival. Kaplan-Meyer curves comparing patients undergoing aortic valve surgery (AVS) and patients that were treated medically (UNOP). Three-year survival was 82.5% in the AVS group and 43.9% in the UNOP group ( p < 0.001). 
Discussion
Our study is the first to demonstrate the positive impact of a TAVI program on referral rates for surgical evaluation (10% increase) and reduction in the rate of UNOP AS (10% decrease). Moreover, the introduction of TAVI was associated with an overall increase in AVR volume of 2.9 AVR cases per 1 TAVI case. Our study also demonstrated no detriment in operative outcomes as a result of the introduction of a TAVI program. Patient survival remained unchanged after the 59% increase in surgical volume.
Aortic Stenosis is a common valvular condition in the elderly population, affecting 1.3-1.4% of patients aged 65-74 years and 2.8-4.6% of patients aged 75 years and older [10] . Current guidelines from the American Heart Association/American College of Cardiology (AHA/ACC) and European Society of Cardiology (ESC) state that patients with severe, symptomatic AS have a class IA guideline for proceeding with AVR, which is associated with increased survival and improvement in symptoms [1, 11] .
These guidelines are supported by recent studies comparing the survival of high-risk, elderly patients with AS undergoing AVS versus medical therapy. Varadarajan et al. showed in a cohort of 277 patients of 80 years and older an adjusted HR of 0.38 ( p < 0.001) favoring AVR compared with medical therapy [12] . Bouma et al. showed in a cohort of 69 high-risk patients with AS that medical therapy carried a relative risk of 3.1 (confidence interval 1.6-6.1) compared with AVR [13] . The placement of aortic transcatheter valves trial (PARTNER) investigators showed that in a randomized cohort of 358 patients that was considered not appropriate for AVR a HR of 0.54 ( p < 0.0001) favoring TAVI versus medical therapy [14] . Our results substantiate the drastically improved survival associated with surgery in a cohort of 841 patients with severe, symptomatic AS (HR = 0.395, p < 0.001).
Other studies have shown the positive impact of TAVI on AVR volume. Kapadia et al. reported that 20% of patients referred for TAVI were not candidates for TAVI and subsequently underwent AVR with good outcomes [15] . Dewey et al. similarly reported that 15% of patients referred for TAVI ultimately underwent surgical AVR [16] . Increased physician awareness and identification of patients who were improperly considered inoperable may be reasons for the increase in AVR volume. It is plausible that patients who were referred for TAVI would not have been otherwise referred for cardiac surgery.
Previous studies have cited the presence of advanced age and comorbid conditions as reasons for not referring patients for surgery [6, 17] . Similar to these studies, our findings show that the presence of comorbid conditions was the second most common reason for nonoperative therapy. However, we did not find advanced age to be a significant reason; this is in agreement with 2006 AHA/ACC guidelines, which states that 'age is not a contraindication to surgery [1] .' Unaddressed in previous studies, we found that patient-family decision was the most common reason for nonoperative therapy. Our study shows that some patients may decide to avoid surgery despite adequate counseling regarding the unequivocal benefit of AVR. Improved patient counseling may further decrease the still significant rate of unoperated AS.
Limitations
Referral rates and AV surgery were determined by evidence of patients being referred to cardiac surgery and subsequently undergoing an operation at our center. Thus, our results may overestimate the rate of unoperated AS, as patients may have followed up with a surgeon at another hospital. On the other hand, some patients were referred directly to our cardiac surgeons for AVR or TAVI, which may underestimate the rate of unoperated AS. Referral rates may be underestimated as patients may have failed to comply with proceeding with surgical evaluation or may have pursued a consultation outside of our institution. The inclusion of high-risk patients from our TAVI program may be diluted in the remainder of patients that had combined procedures (CABG, aortic root reconstruction, ascending AE hemiarch replacement, mitral valve surgery, tricuspid valve repair, and maze procedures). The impact on operative outcomes by the inclusion of more high-risk patients from TAVI referrals is expected in the future.
Conclusion
The introduction of TAVI was associated with an increase in patient referrals and a decrease in the rate of unoperated AS. This positive impact was due to increases in both TAVI and AVR volumes. Increased volume was not associated with worse patient survival. A significant population of patients with severe, symptomatic AS are still treated medically. 
